DermTech, Inc. announced that ECRI completed its evaluation of the Pigmented Lesion Assay (PLA), the foundational assay for the DermTech Melanoma Test (DMT) and changed its rating from Inconclusive to Somewhat Favorable.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.635 USD | +2.42% | +3.77% | -62.88% |
22/04 | North American Morning Briefing : Stock Futures -2- | DJ |
19/04 | Lake Street Downgrades DermTech to Hold From Buy, Price Target is $0.63 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.88% | 21.47M | |
-1.52% | 8.37B | |
+10.68% | 5.84B | |
+27.11% | 5.4B | |
-5.09% | 4.37B | |
-50.89% | 3.23B | |
+14.18% | 2.8B | |
+31.24% | 2.26B | |
-6.47% | 2.22B | |
-1.69% | 1.87B |
- Stock Market
- Equities
- DMTK Stock
- News DermTech, Inc.
- DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay